Neuroendocrinology News

Long-term treatment regimens for neuroendocrine neoplasms can be safely and temporarily delayed in the setting of life-threatening COVID-19-related symptoms, which should be “urgently treated,” according to new guidance.

Adults with Cushing’s disease who took the cortisol synthesis inhibitor osilodrostat were more likely to sustain a normal mean urinary free cortisol level vs. placebo, according to press release from Recordati Rare Diseases.

The FDA approved an oral form of the somatostatin analogue octreotide as a long-term maintenance therapy for people with acromegaly who have responded to and tolerated treatment with octreotide injection or lanreotide.

More than half of a cohort of children and young adults with multiple endocrine neoplasia type 2B had restrictive and obstructive lung abnormalities and 94% showed some degree of diminished lung function, NIH study data showed.

The COVID-19 pandemic presents substantial challenges for pituitary disease management, and clinicians should consider local conditions and hospital resources when opting for surgery vs. medical management, according to new guidance.

In May, Healio readers were interested in sex hormones being investigated for treating COVID-19, greater COVID-19 complications for patients with diabetes and obesity, associations between thyroid dysfunction and working hours, and more.

A cohort of adults with endogenous Cushing’s syndrome experienced a high rate of bone turnover immediately after surgical remission, resulting in a “striking” net increase in bone mineral density for most patients, researchers reported.

Treatment with recombinant human growth hormone does not increase the risk for nonfunctioning pituitary adenoma or craniopharyngioma among adults with GH deficiency, according to an analysis of retrospective data published in The Journal of Clinical Endocrinology & Metabolism.

Alan J. Garber, MD, PhD, MACE, a leading expert on diabetes and cardiometabolic disorders and long-time chief medical editor of Endocrine Today, died Thursday, April 9.

Adults with acromegaly assigned an investigational oral form of the somatostatin analogue octreotide maintained a biochemical response at 36 weeks achieved with previous injection therapy with no serious adverse events, according to findings from the OPTIMAL study accepted for presentation at the Endocrine Society Annual Meeting.